Iron accumulation in mammary tumor suggests a tug of war between tumor and host for the microelement

Anticancer Research

Volumn 27, Issue 5 A, 2007, Pages 3059-3065

  Freitas, Isabel ^a   Boncompagni, Eleonora ^a   Vaccarone, Rita ^a   Fenoglio, Carla ^a   Barni, Sergio ^a   Baronzio, Gian Franco ^b  

^a UNIVERSITY OF PAVIA   (Italy)

^b Policlinico di Monza   (Italy)

Author keywords

Hemosiderin; Iron; Liver; Macrophages; Spleen; Stromal cells; Tumor

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; HEMOSIDERIN; IRON;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CARCINOMA; BREAST TUMOR; CELL INVASION; CELL METABOLISM; CONTROLLED STUDY; FEMALE; INTERSTITIAL FLUID; IRON STORAGE; LIVER CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; TUMOR CELL;

ANIMALS; FEMALE; FERRIC COMPOUNDS; GENES, ERBB-2; LIVER; MAMMARY NEOPLASMS, EXPERIMENTAL; MAMMARY TUMOR VIRUS, MOUSE; MICE; MICE, TRANSGENIC; SPLEEN; STROMAL CELLS;

EID: 35349008009     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Kwok JC and Richardson DR: The iron metabolism of neoplastic cells: alterations that facilitate proliferation? Crit Rev Hematol Oncol 42: 65-78, 2002.
2. Frausto da Silva JJR and Williams RJP: The Biological Chemistry of the Elements. The Inorganic Chemistry of Life. Oxford, Oxford University Press, pp. 340-399, 2001.
3. Brock JH: The physiology of lactoferrin. Biochem Cell Biol 80: 1-6, 2002.
4. Fandrey J, Gorr TA and Gassmann M: Regulating cellular oxygen sensing by hydroxylation. Cardiovasc Res 71: 642-651, 2006.
5. Hentze MW, Muckenthaler MU and Andrews NC: Balancing acts: molecular control of mammalian iron metabolism. Cell 117: 285-297, 2004.
6. Ganz T and Nemeth E: Regulation of iron acquisition and iron distribution in mammals. Biochim Biophys Acta 1763: 690-699, 2006.
7. Searle J, Leggett BA, Crawford DHG and Powell LW: Iron storage diseases. In: Pathology of the Liver. MacSween RNM, Burt AD, Portmann BC, Ishak KG, Scheuer and Anthony PP (eds.). Edinburgh, Churchill Livingstone, pp. 257-272, 2002.
8. Fleming MD and Andrews NC: The liver and iron. In: The Liver: Biology and Pathobiology. Arias IM, Boyer JL, Chisari FV, Fausto N, Schachter D and Shafritz D (eds.). Philadelphia, Lippincott Williams & Wilkins, pp. 345-359, 2001.
9. Buss JL, Torti FM and Torti SV: The role of iron chelation in cancer therapy. Curr Med Chem 10: 1051-1064, 2003.
10. Richardson DR: Iron and neoplasia: serum transferrin receptor and ferritin in prostate cancer. J Lab Clin Med 144: 173-175, 2004.
11. Muller CI, Miller CW, Kawabata H, McKenna RJ Jr, Marchevsky AM and Koeffler HP: Do cancer cells selectively mutate HFE to increase their intracellular iron? Oncol Rep 14: 299-303, 2005.
12. Le NT and Richardson DR: The role of iron in cell cycle progression and the proliferation of neoplastic cells. Biochim Biophys Acta 1603: 31-46, 2002.
13. Richardson DR: Therapeutic potential of iron chelators in cancer therapy. Adv Exp Med Biol 509: 231-249, 2002.
14. Sacco MG, Caniatti M, Cato EM, Frattini A, Chiesa G, Ceruti R, Adorni F, Zecca L, Scanziani E and Vezzoni P: Liposome-delivered angiostatin strongly inhibits tumor growth and metastatization in a transgenic model of spontaneous breast cancer. Cancer Res 60: 2660-2665, 2000.
15. Freitas I, Fracchiolla S, Baronzio G, Griffini P, Bertone R, Sitar GM, Barni S, Gerzeli G and Sacco MG: Stem cell recruitment and liver de-differentiation in MMTV-neu (ErbB-2) transgenic mice. Anticancer Res 23: 3783-3794, 2003.
16. Weinberg ED: The role of iron in cancer. Eur J Cancer Prev 5: 19-36, 1996.
17. Pearse AGE: Histochemistry Theoretical and Applied. London, J&A Churchill, pp. 1068-1070, 1130-1131, 1402, 1968.
18. Brunt EM: Pathology of hepatic iron overload. Semin Liver Dis 25: 392-401, 2005.
19. Hoffman FA: Micronutrient requirements of cancer patients. Cancer 55(1 Suppl): 295-300, 1985.
20. Hoffman FA: Metabolic changes in malignancy. In: Influence of Tumor Development on the Host. Liotta LA (ed.). Dordrecht, Kluwer Academic Publ, pp. 18-27, 1989.
21. Gullino PM, Clark SH and Grantham FH: The interstitial fluid of solid tumors. Cancer Res 24: 780-794, 1964.
22. Dvorak HF: Rous-Whipple Award Lecture. How tumors make bad blood vessels and stroma. Am J Pathol 162: 1747-1757, 2003.
23. Celis JE, Gromov P, Cabezon T, Moreira JM, Ambartsumian N, Sandelin K, Rank F and Gromova I: Proteomic characterization of the interstitial fluid perfusing the breast tumor microenvironment: a novel resource for biomarker and therapeutic target discovery. Mol Cell Proteomics 3: 327-344, 2004. (http://proteomics.cancer.dk/cgi-bin/CelisWeb.exe? ImagePage&breast_TIF_IEF) .
24. Weinberg ED: Iron withholding as a defense strategy. In: Anemia of Chronic Disease. Weiss G, Gordeuk VR, Hershko C (eds.). Taylor & Francis, Boca Raton, pp. 255-280, 2005.
25. Jain RK: Transport of molecules, particles, and cells in solid tumors. Annu Rev Biomed Eng 1: 241-263, 1999.
26. Freitas I, Baronzio GF, Bertone V, Griffini P, Gerzeli G, Pontiggia P and Stoward PJ: Stroma formation in Ehrlich carcinoma. I. Oedema phase. A mitosis burst as an index of physiological reoxygenation? Anticancer Res 11: 569-578, 1991.
27. Freitas I, Baronzio GF, Bono B, Griffini P, Bertone V, Sonzini N, Magrassi GR, Bonandrini L and Gerzeli G: Tumor interstitial fluid: misconsidered component of the internal milieu of a solid tumor. Anticancer Res 17: 165-172,1997.
28. Baronzio GF, Gramaglia A, Baronzio A and Freitas I: Influence of tumor microenvironment on thermoresponse: biological and clinical implications. In: Hyperthermia in Cancer Treatment: A Primer. Baronzio GF and Hager D (eds.). Springer, Berlin, pp. 62-86, 2006.
29. Daniels TR, Delgado T, Rodriquez JA, Helguera G and Penichet ML: The transferrin receptor part I: Biology and targeting with cytotoxic antibodies for the treatment of cancer. Clin Immunol 121: 144-158, 2006.
30. Nelson CM and Bissell MJ: Of extracellular matrix, scaffolds, and signaling: tissue architecture regulates development, homeostasis, and cancer. Annu Rev Cell Dev Biol 22: 287-309, 2006.
31. O'Dell BL: Roles for iron and copper in connective tissue biosynthesis. Philos Trans R Soc Lond B Biol Sci 294: 91-104, 1981.
32. Hasegawa H, Iida Y, Oguro K, Kojima M and Ichiyama A: Tryptophan hydroxylase activity in serotonin producing mast cells. Dependence on intracellular iron concentration manipulated by permeable chelators. Adv Exp Med Biol 398: 513-517, 1996.
33. Simson JV and Spicer SS: Ferritin particles in macrophages and in associated mast cells. J Cell Biol 52: 536-541, 1972.
34. Whitnall M, Howard J, Ponka P and Richardson DR: A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeutics. Proc Natl Acad Sci USA 103: 14901-14906, 2006.
35. Le NT and Richardson DR: Iron chelators with high antiproliferative activity up-regulate the expression of a growth inhibitory and metastasis suppressor gene: a link between iron metabolism and proliferation. Blood 104: 2967-2975, 2004.
36. Le NT and Richardson DR: Competing pathways of iron chelation: angiogenesis or anti-tumor activity: targeting different molecules to induce specific effects. Int J Cancer 110: 468-469, 2004.
37. Jones DT, Trowbridge IS and Harris AL: Effects of transferrin receptor blockade on cancer cell proliferation and hypoxia-inducible factor function and their differential regulation by ascorbate. Cancer Res 66: 2749-2756, 2006.